Sahoo Pallavi, Kothari Nikhil, Goyal Shilpa, Sharma Ankur, Bhatia Pradeep K
Department of Anaesthesiology and Critical Care, AIIMS, Jodhpur, Rajasthan, India.
Department of Trauma and Emergency (Anaesthesia), AIIMS, Jodhpur, Rajasthan, India.
Indian J Crit Care Med. 2022 Jun;26(6):669-675. doi: 10.5005/jp-journals-10071-24231.
To compare norepinephrine and terlipressin vs norepinephrine alone for management of septic shock.
In this prospective, randomized control trial, 50 adult patients with septic shock were randomized into two groups. Group I received a combination of injection terlipressin 0.02 µg/kg/min (fixed dose) infusion and injection norepinephrine 0.01 µg/kg/min infusion and group II received injection norepinephrine 0.01 µg/kg/min infusion alone. Dose of noradrenaline in both the groups was titrated to achieve the target MAP of 65-70 mm Hg. The data collected were the dose of norepinephrine required to maintain an MAP of above 65 mm Hg, urine output, serum lactate, procalcitonin level, C-reactive protein, sequential organ failure assessment (SOFA) score, total duration of vasopressor support, and incidences of the adverse effects.
The norepinephrine dose in group I vs group II at 12 hours was found to be 0.141 ± 0.067 vs 0.374 ± 0.096 µg/kg/min ( ≤0.005). The serum lactate was lower, and urine output was higher in group I than group II ( <0.05). Group I had a significantly greater reduction in SOFA score in 12 hours than group II. Group I patient also had a significant decrease in the duration of vasopressor administration than group II patients being discharged from the ICU. However, there was no difference in the mortality between the two groups during their ICU stay.
A low-dose continuous infusion of terlipressin and norepinephrine could help attain early resuscitation goals for managing patients with septic shock.
Sahoo P, Kothari N, Goyal S, Sharma A, Bhatia PK. Comparison of Norepinephrine and Terlipressin vs Norepinephrine Alone for Management of Septic Shock: A Randomized Control Study. Indian J Crit Care Med 2022;26(6):669-675.
比较去甲肾上腺素联合特利加压素与单独使用去甲肾上腺素治疗感染性休克的效果。
在这项前瞻性随机对照试验中,50例成年感染性休克患者被随机分为两组。第一组接受特利加压素注射液0.02µg/kg/min(固定剂量)输注联合去甲肾上腺素注射液0.01µg/kg/min输注,第二组仅接受去甲肾上腺素注射液0.01µg/kg/min输注。两组去甲肾上腺素剂量均进行滴定,以达到目标平均动脉压(MAP)为65 - 70mmHg。收集的数据包括维持MAP高于65mmHg所需的去甲肾上腺素剂量、尿量、血清乳酸、降钙素原水平、C反应蛋白、序贯器官衰竭评估(SOFA)评分、血管活性药物支持的总时长以及不良反应的发生率。
发现12小时时第一组与第二组的去甲肾上腺素剂量分别为0.141±0.067与0.374±0.096µg/kg/min(≤0.005)。第一组的血清乳酸水平较低,尿量高于第二组(<0.05)。第一组在12小时内SOFA评分的降低幅度明显大于第二组。与从重症监护病房(ICU)出院的第二组患者相比,第一组患者血管活性药物使用时长也显著缩短。然而,两组在ICU住院期间的死亡率并无差异。
低剂量持续输注特利加压素和去甲肾上腺素有助于实现感染性休克患者的早期复苏目标。
Sahoo P, Kothari N, Goyal S, Sharma A, Bhatia PK. Comparison of Norepinephrine and Terlipressin vs Norepinephrine Alone for Management of Septic Shock: A Randomized Control Study. Indian J Crit Care Med 2022;26(6):669 - 675.